Reirradiation for recurrent craniopharyngioma.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
27
04
2020
revised:
08
07
2020
accepted:
28
07
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
12
12
2020
Statut:
epublish
Résumé
Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy. A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed. We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment. Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.
Identifiants
pubmed: 33305092
doi: 10.1016/j.adro.2020.07.020
pii: S2452-1094(20)30211-6
pmc: PMC7718531
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1305-1310Informations de copyright
© 2020 The Authors.
Références
J Neurosurg. 1998 Oct;89(4):547-51
pubmed: 9761047
J Neurosurg. 2017 Feb;126(2):418-430
pubmed: 27153172
Neurosurgery. 2010 Apr;66(4):688-94; discussion 694-5
pubmed: 20190668
Radiother Oncol. 1993 Apr;27(1):13-21
pubmed: 8327728
Indian J Cancer. 2017 Apr-Jun;54(2):409-414
pubmed: 29469068
Crit Rev Oncol Hematol. 2013 Dec;88(3):514-29
pubmed: 23932582
Radiother Oncol. 1993 Jan;26(1):1-10
pubmed: 8438080
Pediatr Neurosurg. 2000 Oct;33(4):211-8
pubmed: 11124639
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S28-35
pubmed: 20171514
Childs Brain. 1982;9(3-4):188-200
pubmed: 7105884
Neurosurg Focus. 2016 Dec;41(6):E11
pubmed: 27903122
Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409
pubmed: 15807869
Neuro Oncol. 2001 Jul;3(3):159-66
pubmed: 11465396
Endocr Rev. 2014 Jun;35(3):513-43
pubmed: 24467716
J Neurooncol. 2012 May;108(1):133-9
pubmed: 22350375
Neurosurgery. 1980 May;6(5):513-7
pubmed: 7413035
J Neurosurg. 1999 Feb;90(2):237-50
pubmed: 9950494
J Neurosurg. 1985 Jan;62(1):120-7
pubmed: 2578064
Neurosurg Rev. 2010 Jan;33(1):71-81
pubmed: 19669813
J Neurosurg Pediatr. 2015 May;15(5):499-505
pubmed: 25700121
Childs Nerv Syst. 2005 Aug;21(8-9):640-8
pubmed: 16047216
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):714-20
pubmed: 14967425
J Natl Cancer Inst. 2015 Oct 23;108(2):
pubmed: 26498373
Ophthalmology. 1985 Aug;92(8):1118-26
pubmed: 4047605
J Neurosurg. 1990 Jul;73(1):3-11
pubmed: 2352020